Is NRXS or PROF more profitable?

Profound Medical has a net margin of -171.57% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% Profound Medical -171.57% -63.03% -51.24%

Does the media refer more to NRXS or PROF?

In the previous week, Profound Medical had 2 more articles in the media than NeurAxis. MarketBeat recorded 3 mentions for Profound Medical and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.24 beat Profound Medical's score of 0.64 indicating that NeurAxis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NRXS or ELMD?

Electromed has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeurAxis $5.32M 13.46 -$14.63M -$0.78 N/A Electromed $73.78M 2.98 $5.15M $1.31 20.07

Is NRXS or ELMD more profitable?

Electromed has a net margin of 11.34% compared to NeurAxis' net margin of -492.76%. Electromed's return on equity of 15.71% beat NeurAxis' return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% Electromed 11.34% 15.71% 13.37%

Does the media refer more to NRXS or ELMD?

In the previous week, Electromed had 2 more articles in the media than NeurAxis. MarketBeat recorded 3 mentions for Electromed and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.24 beat Electromed's score of 0.60 indicating that NeurAxis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Electromed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is STIM or NRXS more profitable?

Neuronetics has a net margin of -19.62% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% NeurAxis -492.76% N/A -641.25%

Does the media favor STIM or NRXS?

In the previous week, Neuronetics had 9 more articles in the media than NeurAxis. MarketBeat recorded 10 mentions for Neuronetics and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.24 beat Neuronetics' score of 0.49 indicating that NeurAxis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PDEX or NRXS?

Pro-Dex has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $77.55M 2.76 $13.66M $4.13 16.20 NeurAxis $5.32M 13.46 -$14.63M -$0.78 N/A

Is PDEX or NRXS more profitable?

Pro-Dex has a net margin of 17.62% compared to NeurAxis' net margin of -492.76%. Pro-Dex's return on equity of 25.13% beat NeurAxis' return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 17.62% 25.13% 16.02% NeurAxis -492.76% N/A -641.25%

Does the media prefer PDEX or NRXS?

In the previous week, Pro-Dex had 11 more articles in the media than NeurAxis. MarketBeat recorded 12 mentions for Pro-Dex and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.24 beat Pro-Dex's score of 0.72 indicating that NeurAxis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZJYL or NRXS?

NeurAxis has a consensus target price of $13.00, indicating a potential upside of 128.07%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts plainly believe NeurAxis is more favorable than Jin Medical International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings and valuation, ZJYL or NRXS?

Jin Medical International has higher revenue and earnings than NeurAxis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jin Medical International $20.69M 7.54 $1.19M N/A N/A NeurAxis $5.32M 13.46 -$14.63M -$0.78 N/A

Is ZJYL or NRXS more profitable?

Jin Medical International has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%. Company Net Margins Return on Equity Return on Assets Jin Medical International N/A N/A N/A NeurAxis -492.76% N/A -641.25%

Does the media prefer ZJYL or NRXS?

In the previous week, Jin Medical International had 2 more articles in the media than NeurAxis. MarketBeat recorded 3 mentions for Jin Medical International and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.24 beat Jin Medical International's score of 0.77 indicating that NeurAxis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jin Medical International 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeurAxis (NRXS) Competitors

$5.70 -0.05 (-0.87%)

Closing price 04:00 PM Eastern

Extended Trading

$5.72 +0.02 (+0.44%)

As of 07:30 PM Eastern

Compare

NRXS vs. PROF, ELMD, STIM, PDEX, and ZJYL

Should you buy NeurAxis stock or one of its competitors? NeurAxis's main competitors and comparable companies include Profound Medical (PROF), Electromed (ELMD), Neuronetics (STIM), Pro-Dex (PDEX), and Jin Medical International (ZJYL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeurAxis compare to Profound Medical?

NeurAxis (NASDAQ:NRXS) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Profound Medical has a net margin of -171.57% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Profound Medical	-171.57%	-63.03%	-51.24%

NeurAxis has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

In the previous week, Profound Medical had 2 more articles in the media than NeurAxis. MarketBeat recorded 3 mentions for Profound Medical and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.24 beat Profound Medical's score of 0.64 indicating that NeurAxis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by company insiders. Comparatively, 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeurAxis presently has a consensus price target of $13.00, suggesting a potential upside of 128.07%. Profound Medical has a consensus price target of $11.50, suggesting a potential upside of 102.46%. Given NeurAxis' stronger consensus rating and higher possible upside, equities analysts plainly believe NeurAxis is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

NeurAxis has higher earnings, but lower revenue than Profound Medical. NeurAxis is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32M	13.46	-$14.63M	-$0.78	N/A
Profound Medical	$16.10M	12.89	-$42.57M	-$0.98	N/A

Summary

NeurAxis beats Profound Medical on 10 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Electromed?

NeurAxis (NASDAQ:NRXS) and Electromed (NYSE:ELMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Electromed had 2 more articles in the media than NeurAxis. MarketBeat recorded 3 mentions for Electromed and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.24 beat Electromed's score of 0.60 indicating that NeurAxis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Electromed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by insiders. Comparatively, 10.5% of Electromed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Electromed has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32M	13.46	-$14.63M	-$0.78	N/A
Electromed	$73.78M	2.98	$5.15M	$1.31	20.07

NeurAxis has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market. Comparatively, Electromed has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Electromed has a net margin of 11.34% compared to NeurAxis' net margin of -492.76%. Electromed's return on equity of 15.71% beat NeurAxis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Electromed	11.34%	15.71%	13.37%

NeurAxis currently has a consensus target price of $13.00, indicating a potential upside of 128.07%. Electromed has a consensus target price of $43.75, indicating a potential upside of 66.41%. Given NeurAxis' stronger consensus rating and higher probable upside, research analysts clearly believe NeurAxis is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Electromed beats NeurAxis on 10 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 21.1% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Neuronetics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Neuronetics currently has a consensus price target of $4.67, indicating a potential upside of 66.67%. NeurAxis has a consensus price target of $13.00, indicating a potential upside of 128.07%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts plainly believe NeurAxis is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Neuronetics has a net margin of -19.62% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
NeurAxis	-492.76%	N/A	-641.25%

In the previous week, Neuronetics had 9 more articles in the media than NeurAxis. MarketBeat recorded 10 mentions for Neuronetics and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.24 beat Neuronetics' score of 0.49 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeurAxis has lower revenue, but higher earnings than Neuronetics. NeurAxis is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.43	-$39M	-$0.44	N/A
NeurAxis	$5.32M	13.46	-$14.63M	-$0.78	N/A

Summary

NeurAxis beats Neuronetics on 9 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Pro-Dex has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

Pro-Dex currently has a consensus target price of $74.00, suggesting a potential upside of 10.60%. NeurAxis has a consensus target price of $13.00, suggesting a potential upside of 128.07%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts plainly believe NeurAxis is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Pro-Dex has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$77.55M	2.76	$13.66M	$4.13	16.20
NeurAxis	$5.32M	13.46	-$14.63M	-$0.78	N/A

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Pro-Dex had 11 more articles in the media than NeurAxis. MarketBeat recorded 12 mentions for Pro-Dex and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.24 beat Pro-Dex's score of 0.72 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pro-Dex has a net margin of 17.62% compared to NeurAxis' net margin of -492.76%. Pro-Dex's return on equity of 25.13% beat NeurAxis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	17.62%	25.13%	16.02%
NeurAxis	-492.76%	N/A	-641.25%

Summary

Pro-Dex beats NeurAxis on 11 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Jin Medical International?

Jin Medical International (NASDAQ:ZJYL) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

11.8% of NeurAxis shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NeurAxis has a consensus target price of $13.00, indicating a potential upside of 128.07%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts plainly believe NeurAxis is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Jin Medical International has higher revenue and earnings than NeurAxis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jin Medical International	$20.69M	7.54	$1.19M	N/A	N/A
NeurAxis	$5.32M	13.46	-$14.63M	-$0.78	N/A

Jin Medical International has a beta of 7.31, suggesting that its stock price is 631% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

In the previous week, Jin Medical International had 2 more articles in the media than NeurAxis. MarketBeat recorded 3 mentions for Jin Medical International and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 1.24 beat Jin Medical International's score of 0.77 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jin Medical International	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jin Medical International has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
Jin Medical International	N/A	N/A	N/A
NeurAxis	-492.76%	N/A	-641.25%

Summary

NeurAxis beats Jin Medical International on 7 of the 13 factors compared between the two stocks.

Get NeurAxis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXS vs. The Competition

Export

Metric	NeurAxis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$71.58M	$5.55B	$7.21B	$15.01B
Dividend Yield	N/A	1.79%	2.57%	12.21%
P/E Ratio	-3.10	25.06	272.84	25.31
Price / Sales	13.46	72.21	701.69	107.35
Price / Cash	N/A	32.78	77.71	51.48
Price / Book	-21.11	5.99	10.37	6.18
Net Income	-$14.63M	$150.13M	$3.49B	$357.96M
7 Day Performance	-3.55%	-2.23%	-2.20%	-1.61%
1 Month Performance	-9.52%	-3.84%	-0.38%	-3.62%
1 Year Performance	143.59%	10.26%	19.16%	5.95%

NeurAxis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXS NeurAxis	1.8553 of 5 stars	$5.70 -0.9%	$13.00 +128.1%	+137.1%	$71.58M	$5.32M	N/A	19	News Coverage
PROF Profound Medical	2.6153 of 5 stars	$6.80 -0.1%	$11.50 +69.1%	+43.8%	$248.79M	$16.10M	N/A	150	Analyst Downgrade High Trading Volume
ELMD Electromed	3.191 of 5 stars	$27.07 -1.6%	$43.75 +61.6%	+10.6%	$230.15M	$73.78M	36.09	160
STIM Neuronetics	4.1738 of 5 stars	$3.04 +3.8%	$4.50 +48.0%	-7.3%	$223.26M	$149.16M	N/A	180
PDEX Pro-Dex	2.7549 of 5 stars	$60.70 -8.6%	$70.00 +15.3%	+101.3%	$212.73M	$77.55M	14.70	140	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXS) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeurAxis (NRXS) Competitors

NRXS vs. PROF, ELMD, STIM, PDEX, and ZJYL

How does NeurAxis compare to Profound Medical?

Summary

How does NeurAxis compare to Electromed?

Summary

How does NeurAxis compare to Neuronetics?

Summary

How does NeurAxis compare to Pro-Dex?

Summary

How does NeurAxis compare to Jin Medical International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeurAxis (NRXS) Competitors

NRXS vs. PROF, ELMD, STIM, PDEX, and ZJYL

How does NeurAxis compare to Profound Medical?

Is NRXS or PROF more profitable?

Which has more risk & volatility, NRXS or PROF?

Does the media refer more to NRXS or PROF?

Do institutionals and insiders hold more shares of NRXS or PROF?

Do analysts recommend NRXS or PROF?

Which has better valuation and earnings, NRXS or PROF?

Summary

How does NeurAxis compare to Electromed?

Does the media refer more to NRXS or ELMD?

Do insiders & institutionals believe in NRXS or ELMD?

Which has stronger valuation & earnings, NRXS or ELMD?

Which has more volatility and risk, NRXS or ELMD?

Is NRXS or ELMD more profitable?

Do analysts prefer NRXS or ELMD?

Summary

How does NeurAxis compare to Neuronetics?

Do insiders and institutionals hold more shares of STIM or NRXS?

Which has more volatility & risk, STIM or NRXS?

Do analysts prefer STIM or NRXS?

Is STIM or NRXS more profitable?

Does the media favor STIM or NRXS?

Which has preferable valuation & earnings, STIM or NRXS?

Summary

How does NeurAxis compare to Pro-Dex?

Which has more risk & volatility, PDEX or NRXS?

Do analysts recommend PDEX or NRXS?

Which has stronger earnings & valuation, PDEX or NRXS?

Do insiders & institutionals hold more shares of PDEX or NRXS?

Does the media prefer PDEX or NRXS?

Is PDEX or NRXS more profitable?

Summary

How does NeurAxis compare to Jin Medical International?

Do institutionals & insiders believe in ZJYL or NRXS?

Do analysts rate ZJYL or NRXS?

Which has stronger earnings and valuation, ZJYL or NRXS?

Which has more risk & volatility, ZJYL or NRXS?

Does the media prefer ZJYL or NRXS?

Is ZJYL or NRXS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools